Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients ...Middle East

LUND, Sweden, Aug. 2, 2021 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix®▼ (imlifidase) is, as of August 1, reimbursable and available for...

Hence then, the article about hansa biopharma announces reimbursement in the netherlands of idefirix imlifidase as desensitization treatment for highly sensitized kidney transplant patients was published today ( Monday 02/08/2021 - 10:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients )

Also on site :

• Ukraine will try “to get some concessions” from Trump at meeting
• Numbrix 9 - December 28
• Getting hired in 2026 is all about your ‘microcredentials’ says CEO of $1.3 billion learning platform—this is what he tells Gen Z to focus on